Cite

HARVARD Citation

    Eom, K. et al. (2014). Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study. BioMed research international. p. . [Online]. 
  
Back to record